Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003

被引：0
|
作者：
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Hudgens, Stacie
Yu, Zhinuan
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San-Miguel, Jesus F.
机构：
[1] Vancouver Gen Hosp, Vancouver, BC, Canada
[2] Alexandra Hosp, Athens, Greece
[3] Univ Tubingen Hosp, Dept Med, Tubingen, Germany
[4] Univ Hosp Hotel Dieu, Nantes, France
[5] Mayo Clin, Rochester, MN USA
[6] Katholieke Univ Leuven Hosp, Dept Hematol, Louvain, Belgium
[7] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France
[8] Univ Klinikum Heidelberg, Heidelberg, Germany
[9] Ctr Hosp Cote Basque, Bayonne, France
[10] HGTiP, Inst Catala Oncol, Barcelona, Spain
[11] Adelphi Values, Boston, MA USA
[12] Celgene Corp, Summit, NJ USA
[13] Hosp Univ Salamanca, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8583
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003
    Goldschmidt, Hartmut
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in the MM-003 trial.
    Weisel, Katja
    Moreau, Philippe
    Gibson, Craig J.
    Song, Kevin W.
    Saunders, Owain
    Sternas, Lars Axel
    Hong, Kevin
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI)
    Weisel, Katja C.
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Weisel, K.
    Dimopoulos, M.
    Moreau, P.
    Lacy, M.
    Song, K.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Banos, A.
    Oriol, A.
    Alegre, A.
    Chen, C.
    Cavo, M.
    Garderet, L.
    Ivanova, V.
    Martinez-Lopez, J.
    Yu, X.
    Sternas, L.
    Jacques, C.
    Zaki, M.
    San Miguel, J.
    HAEMATOLOGICA, 2013, 98 : 105 - 105
  • [5] ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Delforge, M.
    Dimopoulos, M.
    Weisel, K.
    Moreau, P.
    Lacy, M.
    Song, K.
    Karlin, L.
    Goldschmidt, H.
    Banos, A.
    Oriol, A.
    Alegre, A.
    Chen, C.
    Cavo, M.
    Garderet, L.
    Ivanova, V.
    Martinez-Lopez, J.
    Yu, X.
    Sternas, L.
    Jacques, C.
    Zaki, M.
    Miguel, J.
    HAEMATOLOGICA, 2013, 98 : 329 - 330
  • [6] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
    Schey, Steve
    Dhanasiri, Sujith
    Lee, Dawn
    Sternas, Lars
    Yu, Xin
    Zaki, Mohamed H.
    Elvidge, Jamie
    O'Dwyer, Michael
    BLOOD, 2014, 124 (21)
  • [7] Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Weisel, Katja
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Spencer, Andrew
    Knop, Stefan
    Renner, Christoph
    Bahlis, Nizar J.
    Amatya, Ramesh
    Yu, Xin
    Monzini, Mara Silvia
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian J.
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
  • [8] Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)
    Cavo, Michele
    Corradini, Paolo
    Di Raimondo, Francesco
    Petrini, Mario
    Cafro, Anna Maria
    di Toritto, Tommaso Caravita
    Offidani, Massimo
    Semenzato, Gianpietro
    Zambello, Renato
    Lazzaro, Antonio
    Petrucci, Maria Teresa
    Rodeghiero, Francesco
    Simcock, Mathew
    Slaughter, Ana
    Herring, Jennifer
    Peluso, Teresa
    Palumbo, Antonio
    BLOOD, 2015, 126 (23)
  • [9] An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Corradini, Paolo
    Cavo, Michele
    Delforge, Michel
    Weisel, Katja C.
    Ocio, Enrique M.
    Di Raimondo, Francesco
    Hansson, Markus
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Peluso, Teresa
    Sternas, Lars
    Zaki, Mohamed H.
    Moreau, Philippe
    BLOOD, 2015, 126 (23)
  • [10] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for Res crossover.
    Morgan, Gareth J.
    San Miguel, Jesus
    Dhanasiri, Sujith
    Lee, Dawn
    Palumbo, Antonio
    Facon, Thierry
    Zaki, Mohamed H.
    Yu, Xin
    Sternas, Lars Axel
    Jacques, Christian
    Weisel, Katja C.
    Offner, Fritz
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345